Holen Sie sich die Stockscreener-App
33.62
6.17%
-2.21
Vorhandelsmarkt:
32.70
-0.92
-2.74%
Schlusskurs vom Vortag:
$35.83
Offen:
$36.78
24-Stunden-Volumen:
28.00M
Relative Volume:
0.99
Marktkapitalisierung:
$7.32B
Einnahmen:
$1.78B
Nettoeinkommen (Verlust:
$164.40M
KGV:
48.72
EPS:
0.69
Netto-Cashflow:
$236.51M
1W Leistung:
-6.74%
1M Leistung:
-34.54%
6M Leistung:
-45.07%
1J Leistung:
+54.29%
1-Tages-Spanne:
$33.47
$37.22
1-Wochen-Bereich:
$33.47
$38.09
52-Wochen-Spanne:
$21.36
$72.98
Hims Hers Health Inc Stock (HIMS) Company Profile
Firmenname
Hims Hers Health Inc
Sektor
Telefon
415-851-0195
Adresse
2269 CHESTNUT ST, SAN FRANCISCO
Vergleichen Sie HIMS mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
HIMS
Hims Hers Health Inc
|
33.62 | 8.16B | 1.78B | 164.40M | 236.51M | 0.69 |
|
ZTS
Zoetis Inc
|
115.89 | 51.60B | 9.40B | 2.65B | 2.24B | 5.935 |
|
TAK
Takeda Pharmaceutical Co Adr
|
14.06 | 44.51B | 29.63B | 260.53M | 5.51B | 0.0788 |
|
HLN
Haleon Plc Adr
|
9.60 | 42.35B | 14.26B | 1.98B | 2.47B | 0.4327 |
|
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
24.28 | 28.04B | 16.70B | -157.13M | 1.19B | -0.1446 |
|
UTHR
United Therapeutics Corp
|
474.72 | 20.52B | 3.08B | 1.24B | 1.07B | 25.61 |
Hims Hers Health Inc Stock (HIMS) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-10-21 | Eingeleitet | KeyBanc Capital Markets | Sector Weight |
| 2025-06-23 | Herabstufung | Needham | Buy → Hold |
| 2025-06-04 | Bestätigt | Needham | Buy |
| 2025-04-29 | Herabstufung | TD Cowen | Buy → Hold |
| 2025-02-18 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2025-01-10 | Herabstufung | Citigroup | Neutral → Sell |
| 2025-01-07 | Eingeleitet | BTIG Research | Buy |
| 2024-12-17 | Eingeleitet | Morgan Stanley | Overweight |
| 2024-11-14 | Herabstufung | BofA Securities | Buy → Underperform |
| 2024-08-22 | Eingeleitet | Needham | Buy |
| 2024-08-09 | Herabstufung | Imperial Capital | Outperform → In-line |
| 2024-05-22 | Herabstufung | Citigroup | Buy → Neutral |
| 2024-04-16 | Herabstufung | Jefferies | Buy → Hold |
| 2024-04-10 | Eingeleitet | Canaccord Genuity | Buy |
| 2024-02-28 | Hochstufung | Imperial Capital | In-line → Outperform |
| 2024-02-26 | Eingeleitet | Leerink Partners | Market Perform |
| 2023-12-07 | Eingeleitet | Imperial Capital | In-line |
| 2023-07-28 | Eingeleitet | TD Cowen | Outperform |
| 2023-04-11 | Eingeleitet | Robert W. Baird | Neutral |
| 2023-02-09 | Hochstufung | Jefferies | Hold → Buy |
| 2022-11-08 | Hochstufung | BofA Securities | Neutral → Buy |
| 2022-11-08 | Hochstufung | SVB Leerink | Mkt Perform → Outperform |
| 2022-10-17 | Herabstufung | Piper Sandler | Overweight → Neutral |
| 2022-09-07 | Eingeleitet | Truist | Hold |
| 2022-07-15 | Eingeleitet | SVB Leerink | Underperform |
| 2022-04-14 | Eingeleitet | Guggenheim | Buy |
| 2022-04-01 | Fortgesetzt | Credit Suisse | Outperform |
| 2022-03-10 | Eingeleitet | Deutsche Bank | Hold |
| 2021-12-02 | Eingeleitet | Jefferies | Hold |
| 2021-11-11 | Hochstufung | Piper Sandler | Neutral → Overweight |
| 2021-07-06 | Eingeleitet | BofA Securities | Neutral |
| 2021-05-20 | Hochstufung | Credit Suisse | Neutral → Outperform |
| 2021-04-21 | Eingeleitet | Truist | Hold |
| 2021-03-09 | Eingeleitet | Credit Suisse | Neutral |
| 2021-03-02 | Hochstufung | Citigroup | Neutral → Buy |
| 2021-02-17 | Eingeleitet | Citigroup | Neutral |
| 2021-02-12 | Eingeleitet | Piper Sandler | Neutral |
| 2021-02-08 | Eingeleitet | Tigress Financial | Buy |
Alle ansehen
Hims Hers Health Inc Aktie (HIMS) Neueste Nachrichten
OMCL or HIMS: Which Is the Better Value Stock Right Now? - sharewise.com
Hims & Hers Health: A Notable Shift Toward Core - Smartkarma
HIMS Has Been a Roller Coaster Ride. Should Investors Hop On? - MarketBeat
Hims & Hers Health Insider Sold Shares Worth $853,490, According to a Recent SEC Filing - MarketScreener
Hims & Hers Health Stock (HIMS) Opinions on Q3 Earnings and Competitive Challenges - Quiver Quantitative
Hers Health Inc. stock surprise with earnings upside2025 Geopolitical Influence & Weekly Breakout Watchlists - newser.com
Analysts Have Conflicting Sentiments on These Healthcare Companies: NRX Pharmaceuticals (NRXP), LifeMD (LFMD) and Hims & Hers Health (HIMS) - The Globe and Mail
Parents Sue Hims After Washington State Student’s Suicide - USA Herald
Hims & Hers Plunges 15.6% in 3 Months: Time to Hold the Stock or Sell? - TradingView
Commit To Purchase Hims & Hers Health At $20, Earn 27.2% Using Options - Nasdaq
Is Trending Stock Hims & Hers Health, Inc. (HIMS) a Buy Now? - Yahoo Finance
The Price Is Right For Hims & Hers Health, Inc. (NYSE:HIMS) Even After Diving 29% - simplywall.st
Telehealth Co. Hims Sued Over College Student's Suicide - Law360
Key facts: Hims & Hers shares fall 4.9%; Deb Autor appointed Chief Policy Officer - TradingView
Why Hims & Hers Health (HIMS) Shares Are Trading Lower Today - Finviz
What's Going On With Hims & Hers Health Shares Monday? - Benzinga
Hims & Hers Health board approves $250 million share repurchase program - Investing.com Nigeria
Hims & Hers Health stock rises after announcing $250 million buyback program - MSN
Hims & Hers names ex-FDA official Deb Autor as first policy chief - Reuters
Hims & Hers health authorizes $250 million share repurchase program - MSN
Hims & Hers Health, Inc. Appoints Deb Autor as the First Chief Policy Officer - MarketScreener
Hims & Hers Announces New $250 Million Share Repurchase Program – Retail Sees A Steady Trading Range For The Stock - Stocktwits
Hims & Hers Health effects new up to $250M stock buyback program, shares up ~2% - MSN
Hims & Hers Health Announces New Share Buyback Program - TipRanks
Hims & Hers Health effects new up to $250M stock buyback program, shares up ~2% (HIMS:NYSE) - Seeking Alpha
Hims & Hers announces $250 million share repurchase program - Investing.com India
Hims & Hers Health Announces New Share Repurchase Program - TradingView
Hims & Hers Health, Inc. Announces $250 Million Share Repurchase Program Authorization - Hims Investor Relations
Hims & Hers appoints former FDA leader Deb Autor as first CPO - Investing.com Canada
Hims & Hers Names Deb Autor as Chief Policy Officer to Lead Global Policy and Regulatory Strategy - The AI Journal
Hims & Hers appoints former FDA leader Deb Autor as first CPO By Investing.com - Investing.com South Africa
Why I’m Joining Hims & Hers - Hims & Hers Newsroom
Hims & Hers Launches ‘Labs’ to Expand Into Data-Driven Diagnostics - Global Cosmetics News
Hims & Hers Health’s Valuation in Focus After Wrongful Death Lawsuit Raises New Questions - Yahoo Finance
Hims & Hers Enters Direct-to-Consumer Lab Testing %%sep%% %%sitename%% - Newsweek
Hims & Hers Introduces Labs With Annual Plans For Comprehensive Testing - Benzinga
Family Alleges Hims & Hers Health, Inc.’s Rush Into Mental Healthcare Violated Washington Law and Resulted in Son’s Death - The Manila Times
Family Alleges Hims & Hers Health, Inc.’s Rush Into Mental - GlobeNewswire
Hims & Hers Health Stock (HIMS) Opinions on Q3 Earnings and New Platform Launch - Quiver Quantitative
Why Hims & Hers Health Shares Are Sliding - TipRanks
1 Healthcare Stock to Consider Right Now and 2 Facing Headwinds - Finviz
Hims & Hers Stock Logs 3-Day Losing Streak As Truist Calls Out Klarna GLP-1 Changes — Retail Sees Fresh Buy Zone - Stocktwits
Hims & Hers Stock Plunge: Expansion Fails to Impress Investors - AD HOC NEWS
Hims & Hers Bets on Lab Testing to Boost Growth - The Wall Street Journal
Health Care Flat as Traders Rotate Into Sectors Less Dependent on AI Boom -- Health Care Roundup - MarketWatch
Family of WSU student files wrongful death lawsuit against Hims & Hers over antidepressant prescription - NonStop Local KHQ
Family of WSU student who died by suicide in 2023 sues Hims & Hers Health, Theta Chi fraternity for wrongful death - KREM
Key facts: Hims & Hers Health expands telehealth services; Officer sells shares - TradingView
Looking For A Squeeze? Here Are The Top 10 Most Shorted Stocks - Benzinga
Family of WSU student suing telehealth company, fraternity alleging responsibility in suicide - KXLY.com
Hims & Hers Health (HIMS) Launches Labs for Preventive Care - GuruFocus
Finanzdaten der Hims Hers Health Inc-Aktie (HIMS)
Umsatz
Nettogewinn
Free Cashflow
ENV
1.03%
0.67%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):